SonoMotion, a medical device company that is developing noninvasive solutions for kidney stones, announced it has been awarded a $2.2 million NIH grant and successfully completed patient enrollment in the SOUND Break Wave pivotal clinical trial. And the SOUND trial is a 64-patient, prospective, multi-center, non-randomized study designed to evaluate the safety and effectiveness of the Break Wave system for fragmentation of stones in the kidney or ureter. The trial results serve as the clinical basis for the planned Break Wave device FDA 510(k) submission.
Stone Clear, which is SonoMotion’s initial solution for facilitating clearance of post-lithotripsy residual fragments, was granted FDA 510(k) de novo clearance in October 2024. And the Stone Clear and Break Wave devices will operate on the same platform, providing a complete solution for the noninvasive treatment of kidney stones. Kidney stones affect 1 in 10 people in the U.S., resulting in 750,000+ annual procedures, typically requiring anesthesia and a surgical suite and costing billions.
KEY QUOTES:
“Patients with obstructive kidney stones typically require treatment in a surgical suite under conscious sedation or general anesthesia. The Break Wave device provides patients with a noninvasive, anesthesia-free treatment option that can be performed at a variety of healthcare settings. Break Wave has the potential to provide expedited stone treatment and faster convalescence allowing patients to return to their lives sooner than with traditional treatments.”
Dr. James Johannes, Director at the Center of Endourology and Stone Disease, Lehigh Valley Health Network
“We are excited to receive the Fastrack SBIR grant from the NIH. This is a testament to our mission to fundamentally change how kidney stones are treated. SonoMotion’s platform has the potential to be a first-line treatment for kidney stones, offering a solution for patients who want to avoid anesthesia, without the wait time or cost associated with a surgical suite. Thank you to our investigators and research teams for helping us complete enrollment in our pivotal trial.”
Oren Levy, PhD, Co-Founder and CEO, SonoMotion
